Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
100 participants
INTERVENTIONAL
2017-10-01
2018-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients
NCT01490229
Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients
NCT02001883
Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients
NCT01807078
Plant Sterols Effect on Previous Statin Therapy
NCT02089867
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons
NCT00481351
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
statin + ezetimibe
Low dose statin associated with ezetimibe
statin + ezetimibe
Combination of two drugs
statin + ezetimibe + Nutraceuticals
Combination of two grus plus nutraceuticals
statin + ezetimibe + Nutraceuticals
Low dose statin associated with ezetimibe and Nutraceuticals
statin + ezetimibe
Combination of two drugs
statin + ezetimibe + Nutraceuticals
Combination of two grus plus nutraceuticals
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
statin + ezetimibe
Combination of two drugs
statin + ezetimibe + Nutraceuticals
Combination of two grus plus nutraceuticals
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Roma La Sapienza
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Francesco Pelliccia
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carlo Gaudio, MD
Role: STUDY_CHAIR
Sapienza University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sapienza University
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Marazzi G, Campolongo G, Pelliccia F, Calabro Md P, Cacciotti L, Vitale C, Massaro R, Volterrani M, Rosano G. Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment. Am J Cardiol. 2019 Jan 15;123(2):233-238. doi: 10.1016/j.amjcard.2018.09.041. Epub 2018 Oct 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
123/D/2017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.